Terry Chrisomalis - Comments
Pharma/Biotech Analyst

I am a graduate of  Industrial and Business Service Management. I have been investing and writing about biotechnology stocks for many years now and have extensive experience writing about the science and companies themselves. I am a contributor to more

Latest Comments
Protalix BioTherapeutics Pipeline Progress
6 days ago

PRX-110 for cystic fibrosis and OPRX-106 for irritable bowel syndrome are other pipeline products.

In this article: PLX, SNY
Bellicum Is Worth A Look With Multiple Catalysts On The Way In 2nd Half Of 2019
10 months ago

That's hard to say because it depends on negotiations. But Rivo-cel in Europe in pediatric setting can garner $500 million to $700 million in revenue. On top of the phase 2/3 THRIVE study which is ongoing right now, once data for that is revealed if it is successful with primary endpoint that adult population would add the potential for $3 to $4 billion in revenue. So on that basis I would say a very good chance. Having said that it's hard to say when it will come. Because big deals take about 3 to 6 months to negotiate. So without knowing when they started talks it's hard to say exactly.

In this article: BLCM
Bellicum Is Worth A Look With Multiple Catalysts On The Way In 2nd Half Of 2019
11 months ago

That's because before the recent influx of cash investors were worried about dilution or cash raise. They knew that cash was low and they were going to need more cash. So any catalyst of course would have cause new lows. However, now with Baker Brothers and financing completed they have cash slightly past 2021. They are good on cash now. I don't believe any positive catalyst will have a negative reaction. Also, it depends. If Bellicum finds a partner for instance for Europe on rivo-cel with upfront cash and milestone payments it will trade higher. But thanks for your opinion.

In this article: BLCM
Finally A Real Cancer Diagnosis Breakthrough?
1 year ago

Well right now the company is starting to commercialize so it wont' be like instant gratification. But as long as tests can be approved in multiple territories it will get better.

In this article: TOMDF, AMBS
Finally A Real Cancer Diagnosis Breakthrough?
1 year ago

Sorry for your Mother, yes such earlier detection will be needed in the future to save more lives.

In this article: TOMDF, AMBS
Finally A Real Cancer Diagnosis Breakthrough?
1 year ago

Basically, instead of waiting to detect the cancer itself when its just about late in the game, it detects how the immune system reacts to the cancer. This leads to a much earlier diagnosis.

In this article: TOMDF, AMBS
Finally A Real Cancer Diagnosis Breakthrough?
1 year ago

bottom line the way the test works it can detect disease at an earlier stage of the process. This helps with both the patient being treated earlier and at a cheaper cost.

In this article: TOMDF, AMBS
Finally A Real Cancer Diagnosis Breakthrough?
1 year ago

That's because big pharma companies have a better shot at succeeding in clinical trials. The failure rate for developing drugs to treat Alzheimer's is low, but the problem is acquisition costs of patients and recruit patients who definitely have the disease. Also as Herman says to get an earlier diagnosis would mean that someone with Alzheimer's stands a better shot at being treated.

In this article: TOMDF, AMBS
Finally A Real Cancer Diagnosis Breakthrough?
1 year ago

Yes the science of it is quite interesting.

In this article: TOMDF, AMBS
Finally A Real Cancer Diagnosis Breakthrough?
1 year ago

basically it's a cheaper blood test and it can detect cancer at an earlier stage than other tests. That's because it doesn't look at detecting cancer itself, it detects how your immune system reacts to the cancer.

In this article: TOMDF, AMBS
1 to 10 of 82 comments
1 2 3 ... 9